html5-img
1 / 19

Cadila Healthcare Ltd

Cadila Healthcare Ltd. Investor Presentation March 2009. OUR VISION. Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010 ;

fiona-foreman
Download Presentation

Cadila Healthcare Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cadila Healthcare Ltd Investor Presentation March 2009

  2. OUR VISION Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020.

  3. ZYDUS CADILA - SNAPSHOT • Ranked 5th in Indian formulations market. (Source : ORG IMS MAT Jan-09). • Presence in developed generics markets (US, Europe, Japan) and emerging markets (Brazil, South Africa, CIS, Taiwan, Philippines and select other markets in Asia Pac and Africa region). Formulations exports grew by ~70% in last 4 years. • Market leader in niche consumer healthcare business with strong brands • Focusing on R&D – spending 6-7% of revenues p.a. • Consol. ($ Mio.)FY 07-08FY 06-07% GrFY 08-09 (9 m) % Gr Operating Income 517 406 27% 25% Operating PAT 56 46 23% 39% Note : For convenience of understanding, INR numbers have been converted into USD by taking average exchange rate of USD 1 = INR 45.

  4. STATE OF THE ART FACILITIESAND INFRASTRUCTURE • Formulations – five manufacturing plants • Moraiya (Gujarat) - Largest integrated facility in Asia • Baddi (Himachal Pradesh) – for domestic and regulated markets • Sikkim – for domestic market • Goa – for semi regulated markets • Brazil – for catering to branded generics market • Consumer Products • Moraiya (Gujarat) – for Nutralite • APIs and Fine Chemicals – three plants • Ankleshwar and Dabhasa (Gujarat) • Fine chemicals facility at Ahmedabad (Gujarat) • Contract Manufacturing • Mumbai – for Pantoprazole intermediates for Zydus Nycomed JV • Ahmedabad – for cytotoxic injectibles for Zydus Hospira JV • Ahmedabad – for cytotoxic facility for Zydus BSV JV

  5. CORE BUSINESS AREAS AND REVENUE BREAK-UP (FY 07-08) Revenue break-up by segment Revenue break-up by region

  6. FINANCIAL HIGHLIGHTS • 27% • 31% • 21% • 23% • 23% • 23% • 24% • 24% Note : Operating Net Profit = Net Profit - Exceptional Items - Non Operating Items - Non Operating Forex Gains / Losses

  7. INDIA FORMULATIONS – SHIFT OF FOCUS Portfolio shift from acute to life style and chronic segments 2007-08 2000-01

  8. ACHIEVEMENTS IN INDIAN MARKET • Zydus Cadila ranks 5th with $ ~275 Mio. sales. (Source: ORG IMS MAT Jan-09) • Leading positions in the key therapeutic segments – Cardiovascular, Gastrointestinal, Female Healthcare and Respiratory (participated market segments, as per ORG IMS MAT Jan-09) • 16 Zydus brands feature amongst the top 300 brands. (Source: ORG IMS MAT Jan-09) • Exploring opportunities in rural market – next growth driver • Launched >40 new products and line extensions so far in FY 08-09, of which 15 were 1st in India. • Entered dermatology market thru acquisition of Liva Healthcare • Strengthened position in Neutraceuticals,Orthopedic, Diagnostics and Cosmetology segments by adding devoted task forces

  9. INTERNATIONAL FORMULATIONS - TWO FOLD FOCUS • Developed generics markets • US - the largest generic market • Zydus Pharmaceuticals USA Inc. • Europe - Zydus France SAS • Laboratories Combix, Spain • Japan- • Nippon Universal Pharmaceuticals Ltd. • Emerging markets • Brazil – Nikkho (Branded), Zydus Brazil (Generics) • Asia Pacific- Sri Lanka, Myanmar, Taiwan, Philippines • Africa, Middle East – South Africa (Simayla), Sudan, Uganda, Algeria • CIS - Russia , Ukraine International sales projections Formulations-emerging markets Formulations- developed markets APIs/intermediates- exports 2007-08 US$ 217 Mio 2010-11 E US$ 450 Mio

  10. US – MARKETING PLAN AND ACHIEVEMENTS SO FAR • World’s largest generics market at ~ $ 35 bn, growing at 10-12% (Source : IGPA) • Started operations in 2005 • Over half of the products use own API. • Plan to file 12-15 ANDAs p.a. • Launched 22 products. Plan to launch 8-10 products every year. • Market share ranges between 5-25% in these products. • Sales ~$ 79 Mio. (CY 2008) • Rated as one of the fastest growing generic companies in US by IMS Robust regulatory pipeline

  11. EUROPE – KEY INITIATIVES SO FAR • New Markets • Entered Spanish market (5th largest in Europe) by acquiring Laboratories Combix • Planning to enter select other markets • Product Launches • Launched >100 generic presentations in France • Plan to launch of 12-15 products p.a. in France • Focus on Generics • Eur 2 bn market, growing at ~11% (IMS) • Over 2% share in participated market, one of the fastest growing companies. Leveraging India’s lower cost Generics to drive our French business 29.0 21.8 11.5

  12. BRAZIL – KEY INITIATIVES • $ 10 bn pharmaceutical market, growing at ~12% (Source : IMS) • Entered generics market in 2005-06 thru 100% subsidiary, Zydus Healthcare Brazil Ltda • Filed dossiers for 40 products so far, of which 18 have been approved and all have been launched • Acquired of Nikkho do Brazil Ltda. in 2007-08 provides entry into fast growing, profitable and sustainable branded generics segment. • A profit-making co., Nikkho has a mfg. facility and strong marketing and distribution network in Brazil. • Present basket of ~20 brands has been expanded with launch ofseveral new brands from pipeline of existing brands and few acquired brands. • Crossed sales of BR 68 Mio. (~$ 35 Mio.) in CY 2008 in Brazil, expected to grow at over 20% annually.

  13. JAPAN AND OTHER EMERGING GLOBAL MARKETS • Acquired Nippon Universal Pharma. Ltd. in 2007-08 to gain entry in generics market of Japan, valued at ~$3 bn, growing at ~12% (Source : IGPA). • Plan to introduce new products in Japan through in-licensing route as well product registrations from India. • Presence in over20 semi / non regulated emerging markets. • Amongst top 3 Indian pharma cos. in Sri Lanka, Myanmar, Uganda and Sudan. • Focusing and developing base in rapidly growing markets of Russia, South Africa, Taiwan and Philippines. • Recently acquired majority stake in Simayla Pharma, South Africa. Plan to launch several new products in South Africa within next 3 years, from strong pipeline which we have built from India. • Exports to these markets grew by >20% in last 4 years and crossed $ 20 Mio. mark in FY07-08.

  14. CONSUMER HEALTHCARE – BUILDING STRONG BRANDS • Presence in low calorie sweetener and skincare products business in India since more than 15 years. • Sugar Freegroup - the healthier alternative to sugar • Market leader in India with market share of >75% (Source : AC Nielsen). • Growing at CAGR of over 20% for last 3 years, the brand crossed $ 14 Mio. sales mark in FY 07-08. • Everyuthrange of skincare products have also been growing at CAGR of ~ 20% for last 3 years. • Acquired stake in Carnation Nutra-Analogue Foods Ltd., the manufacturers of Nutralite, India’s largest selling margarine • Revamped brand Nutralite post acquisition, which crossed sales of $12 Mio. with 32% growth and registered positive bottom-line in FY 07-08. • Restructuring of consumer business, with de-merger of consumer business from Cadila in Carnation, which is now Zydus Wellness Ltd., is aimed at unlocking business synergies and shareholders’value.

  15. CONTRACT MANUFACTURING - EXCITING PROSPECTS • Zydus Nycomed JV – most successful contract manufacturing JV in India • State of the art API mfg. plant for Pantoprazole intermediates • Plan to expand scope of the JV, with more APIs to be sources by Nycomed from this JV over next 2-3 years • Zydus Hospira - JV for oncology injectables (Generics) • State of the art cytotoxic facility located in an SEZ near Ahmedabad. • Commercial production to start from Q1 FY 09-10 • Full capacity utilisation by FY 10-11. • Zydus BSV - JV for oncology NDDS • State of the art mfg. plant in SEZ near Ahmedabad • Launched NDDS product in India in 2008 as Nudoxa • 33 other contracts with innovator and generic MNCs with peak revenue potential of US$ 45 Mio.

  16. RESEARCH FOCUS Scientific Talent Pool ~ 800 • Zydus Research Centre (ZRC) • Located in Ahmedabad • Focused on NME Research & NDDS • Pharmaceutical Technology Centre (PTC) • 2 centers – one located in Ahmedabad, another in Mumbai • Focused on Finished Dosage Form Development & NDDS R&D Spends – FY 07-08 • API Process Research • Located in Ankleshwar/Ahmedabad • Focused on Process Development 62% 32% 6% ~ $ 35 Mio. (~7% of revenues)

  17. ZYDUS RESEARCH CENTER - INVESTING FOR THE FUTURE • NME Research, Biologicals (Biogenerics) & NDDS. • Therapeutic Area: Dyslipidemia, Diabetes, Obesity, Inflammation. • Infrastructure for target identification to pre-clinical research / early clinical development. • Multiple candidates under preclinical stage. NME Pre Clinical IND Filing Phase 1 Phase 2 Phase 3 NME Pipeline ZYH1 Dyslipidemia ZYI1 Inflammation ZYH2 Diabetes ZY01 Obesity ZYH7 Dyslipidemia ZYT1 Dyslipidemia

  18. HIGHLIGHTS FROM LATEST FINANCIAL RESULTS Note : Operating Net Profit = Net Profit - Exceptional Items - Non Operating Items - Non Operating Forex Gains / Losses

  19. Thank You. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.. This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements.The Company also disclaims any obligation to revise any forward-looking statements . The viewers may use their own judgement and are advised to make their own calculations before deciding on any matter based on the information given herein www.zyduscadila.com

More Related